BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 16014699)

  • 1. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
    Tavtigian SV; Deffenbaugh AM; Yin L; Judkins T; Scholl T; Samollow PB; de Silva D; Zharkikh A; Thomas A
    J Med Genet; 2006 Apr; 43(4):295-305. PubMed ID: 16014699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of unclassified missense substitutions in human BRCA1.
    Tavtigian SV; Samollow PB; de Silva D; Thomas A
    Fam Cancer; 2006; 5(1):77-88. PubMed ID: 16528611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
    Abkevich V; Zharkikh A; Deffenbaugh AM; Frank D; Chen Y; Shattuck D; Skolnick MH; Gutin A; Tavtigian SV
    J Med Genet; 2004 Jul; 41(7):492-507. PubMed ID: 15235020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
    Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
    Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
    Spurdle AB; Lakhani SR; Healey S; Parry S; Da Silva LM; Brinkworth R; Hopper JL; Brown MA; Babikyan D; Chenevix-Trench G; Tavtigian SV; Goldgar DE;
    J Clin Oncol; 2008 Apr; 26(10):1657-63. PubMed ID: 18375895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of common BRCA1 and BRCA2 variants.
    Deffenbaugh AM; Frank TS; Hoffman M; Cannon-Albright L; Neuhausen SL
    Genet Test; 2002; 6(2):119-21. PubMed ID: 12215251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics.
    Ernst C; Hahnen E; Engel C; Nothnagel M; Weber J; Schmutzler RK; Hauke J
    BMC Med Genomics; 2018 Mar; 11(1):35. PubMed ID: 29580235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
    Chenevix-Trench G; Healey S; Lakhani S; Waring P; Cummings M; Brinkworth R; Deffenbaugh AM; Burbidge LA; Pruss D; Judkins T; Scholl T; Bekessy A; Marsh A; Lovelock P; Wong M; Tesoriero A; Renard H; Southey M; Hopper JL; Yannoukakos K; Brown M; Easton D; Tavtigian SV; Goldgar D; Spurdle AB;
    Cancer Res; 2006 Feb; 66(4):2019-27. PubMed ID: 16489001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.
    Vallée MP; Francy TC; Judkins MK; Babikyan D; Lesueur F; Gammon A; Goldgar DE; Couch FJ; Tavtigian SV
    Hum Mutat; 2012 Jan; 33(1):22-8. PubMed ID: 21990165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of BRCA1 missense variants of unknown clinical significance.
    Phelan CM; Dapic V; Tice B; Favis R; Kwan E; Barany F; Manoukian S; Radice P; van der Luijt RB; van Nesselrooij BP; Chenevix-Trench G; kConFab ; Caldes T; de la Hoya M; Lindquist S; Tavtigian SV; Goldgar D; Borg A; Narod SA; Monteiro AN
    J Med Genet; 2005 Feb; 42(2):138-46. PubMed ID: 15689452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.
    Tavtigian SV; Byrnes GB; Goldgar DE; Thomas A
    Hum Mutat; 2008 Nov; 29(11):1342-54. PubMed ID: 18951461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
    Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
    Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
    Ostrow KL; McGuire V; Whittemore AS; DiCioccio RA
    Cancer Genet Cytogenet; 2004 Sep; 153(2):177-80. PubMed ID: 15350310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
    Tram E; Savas S; Ozcelik H
    PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.
    Hansen TV; Jønson L; Steffensen AY; Andersen MK; Kjaergaard S; Gerdes AM; Ejlertsen B; Nielsen FC
    Fam Cancer; 2011 Jun; 10(2):207-12. PubMed ID: 21318380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional assays for BRCA1 and BRCA2.
    Carvalho MA; Couch FJ; Monteiro AN
    Int J Biochem Cell Biol; 2007; 39(2):298-310. PubMed ID: 16978908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.